Patents Assigned to Mira Dx, Inc.
  • Biomarkers for predicting tumor response to and toxicity of immunotherapy
    Patent number: 11578371
    Abstract: The invention is directed to biomarkers for predicting a patient's response, both therapeutic and toxic, to immunotherapy.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: February 14, 2023
    Assignee: MIRA DX, INC.
    Inventor: Joanne Weidhaas
  • Methods for treating or preventing cancer in a KRAS-variant patient and for diagnosing risk of developing multiple primary breast tumors
    Patent number: 10278976
    Abstract: The invention relates to methods for preventing cancer in a KRAS-variant subject which include administering to the KRAS-variant subject an amount of estrogen effective to reduce the risk of developing cancer. In another aspect, the invention further relates to methods for treating cancer in a KRAS-variant subject, which include gradually decreasing estrogen exposure in the KRAS-variant subject to reduce the risk of aggressive tumor growth. In another aspect, the invention relates to a method of predicting an increased risk of developing a second, independent breast cancer in a subject. The method can include detecting a single nucleotide polymorphism (SNP) at position 4 of the let-7 complementary site 6 of KRAS in a patient sample wherein the presence of said SNP indicates an increased risk of developing a second, independent cancer in said subject.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: May 7, 2019
    Assignee: Mira Dx, Inc.
    Inventor: Joanne Weidhaas
  • METHODS FOR TREATING OR PREVENTING CANCER IN A KRAS-VARIANT PATIENT AND FOR DIAGNOSING RISK OF DEVELOPING MULTIPLE PRIMARY BREAST TUMORS
    Publication number: 20170360803
    Abstract: The invention relates to methods for preventing cancer in a KRAS-variant subject which include administering to the KRAS-variant subject an amount of estrogen effective to reduce the risk of developing cancer. In another aspect, the invention further relates to methods for treating cancer in a KRAS-variant subject, which include gradually decreasing estrogen exposure in the KRAS-variant subject to reduce the risk of aggressive tumor growth. In another aspect, the invention relates to a method of predicting an increased risk of developing a second, independent breast cancer in a subject. The method can include detecting a single nucleotide polymorphism (SNP) at position 4 of the let-7 complementary site 6 of KRAS in a patient sample wherein the presence of said SNP indicates an increased risk of developing a second, independent cancer in said subject.
    Type: Application
    Filed: December 11, 2015
    Publication date: December 21, 2017
    Applicant: Mira Dx, Inc.
    Inventor: Joanne Weidhaas